ERBB2 and breast carcinoma: The relevance of the difference of monthly costs according to intrinsic molecular subtypes (HER2+ EUR 2661, luminal EUR 881, and triple negative EUR 386) indicates that billing rates should be adapted to subtypes of breast cancer patients.